




# PHARMACEUTICAL 2019

Vistagen Therapeutics Inc.  
Rank 275 of 363





# PHARMACEUTICAL 2019

Vistagen Therapeutics Inc.  
Rank 275 of 363



The relative strengths and weaknesses of Vistagen Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vistagen Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 41% points. The greatest weakness of Vistagen Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 97% points.

The company's Economic Capital Ratio, given in the ranking table, is -31%, being 68% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	11,023
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,458
Liabilities, Non-Current	2,903
Other Assets	48
Other Compr. Net Income	0
Other Expenses	11
Other Liabilities	0
Other Net Income	-135
Other Revenues	0
Property and Equipment	207
Research and Development	7,762
Selling, General and Administrative Expense	6,437

Output Variable	Value in 1000 USD
Assets	11,278
Liabilities	4,362
Expenses	14,211
Revenues	0
Stockholders Equity	6,917
Net Income	-14,346
Comprehensive Net Income	-14,346
Economic Capital Ratio	-31%